Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
EHA 2025 Conference
- Home
- EHA Conference 2025
Durable Outcomes with Fixed-Duration Ibrutinib + Venetoclax: 97% OS at 5.5 Years in CLL/SLL
The Chronic lymphocytic leukemia/ small lymphocytic lymphoma treatment landscape is moving toward fixed-duration, chemotherapy-free regimens using targeted agents. BTK inhibitors combined with venetoclax offer deep remissions and undetectable MRD, with strong long-term outcomes and retreatment potential. This approach reflects a growing preference for time-limited yet effective therapies.
Our Recent Articles
Types / Technology
Indications
Title
Durable Outcomes with Fixed-Duration Ibrutinib + Venetoclax: 97% OS at 5.5 Years in CLL/SLL
Summary
The Chronic lymphocytic leukemia/ small lymphocytic lymphoma treatment landscape is moving toward fixed-duration, chemotherapy-free regimens using targeted agents. BTK inhibitors combined with venetoclax offer deep remissions and undetectable MRD, with strong long-term outcomes and retreatment potential. This approach reflects a growing preference for time-limited yet effective therapies.
Title
Extended IsaKRD vs. ASCT: MIDAS Trial Suggests Equivalent MRD Clearance in MRD-Negative Myeloma
Summary
The phase III MIDAS trial showed that IsaKRD consolidation and ASCT resulted in similar MRD negativity in MRD-negative NDMM patients. No clear benefit was seen with tandem ASCT in MRD-positive patients
Title
Balanced Outcomes with Lower-Dose BESPONSA: 50.9% Remission and 12.2-Month OS in Early Responders Pre-HSCT
Summary
BESPONSA continues to be a practical choice in R/R B-ALL, particularly for older or transplant-ineligible patients needing rapid, off-the-shelf treatment. Despite SOS risks, it offers high remission rates and fills a crucial gap where CAR-T therapies may not be suitable.
Title
Selective CD33 Deletion with Trem-cel Supports Novel Post-Transplant Strategy to Prevent Relapse in AML
Summary
Trem-cel, a gene-edited hematopoietic stem cell therapy, demonstrated high CD33-editing efficiency, rapid engraftment, and favorable safety in patients with CD33-positive AML or high-risk MDS undergoing allogeneic transplant. When combined with post-transplant gemtuzumab ozogamicin maintenance, trem-cel allowed therapeutic exposure with reduced toxicity, suggesting a novel relapse-prevention strategy.
Title
BLINCYTO Outshines Chemo with 3-Year OS of 100% in BCR::ABL1-Like ALL, Reinforcing Its Role in High-Risk Disease.
Summary
BLINCYTO (blinatumomab), the first FDA-approved bispecific antibody, has transformed treatment for B-cell ALL, particularly in MRD-positive and relapsed/refractory cases. Its clinical success and targeted mechanism have positioned it as a foundational therapy in the bispecific space, including in pediatric ALL, where it competes with CAR-T therapies like KYMRIAH.
Title
Progress in Waldenström Macroglobulinemia Treatment: Phase I/II CaDAnCe-101 Findings for BeiGene’s BTK Degrader
Summary
BeiGene presented the Phase I/II (CaDAnCe-101 study) data of BGB-16673, a BTK degrader, a potential first-in-class protein degrader that blocks BTK signaling by tagging BTK for degradation through the cell's proteasome pathway. Data from this ongoing study demonstrate that the novel BTK degrader BGB-16673 was well tolerated and continued to show substantial antitumor activity in pts with heavily pretreated BTK inhibitor-exposed R/R WM, including those with BTK, CXCR4, and TP53 mutations.
Case Studies
Conference Coverage In Various Oncology Conferences
Learn how a big pharma company leveraged conference coverage solutions to comprehensively cover ASCO 2024, ESMO 2023, EHA, and others by meticulous conference planning.
Market Assessment
Find out how a global pharma company evaluated the market potential of asset gained through acquisition.
Product Assessment
Find out how a global pharma company monitored the performances of its wide variety of newly launched oncology products based on Lead and Lag KPIs
R&D Landscape Assessment
Discover how the large pharma client develops API and FD using CDMO competence.
KOL Profiling
Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry.
Newsletter and Whitepapers
Major Hike Anticipated in the AML Market Due to the Presence of a Robust Pipeline
Currently, the AML sphere constitutes a robust pipeline with more than 250+ drugs under different phases of development. Even with the presence of so many therapeutic drugs, there is still a need for targeted palliative care interventions and therapies with lower toxicity and better efficacy. Learn about the recent happenings, ongoing research & development, and significant pharmaceutical companies involved in the AML treatment market.
-market.png&w=3840&q=75)
-market.png&w=3840&q=75)
Get Expert Consultation Now!
Our extensive history and deep knowledge in the field of oncology make us an ideal ally for addressing your urgent business challenges
Leveraging our comprehensive understanding of the oncology pipeline, nuanced grasp of market dynamics, and keen insight into marketing intricacies, we can assist you in devising a highly effective strategy for future success.
Reach out to us to explore potential collaboration opportunities and learn more about the valuable solutions we can provide.
Delivering value through our expansive service offerings
Considering the ever-changing nature of the hematology therapy field, it's crucial to establish a competitive advantage for your business as soon as possible. Our range of consulting services and market research resources positions us well to guide you through obstacles while maximizing your strengths and opportunities.
We provide valuable insights to enhance your competitive edge and develop successful growth strategies. Join us on a journey to uncover opportunities and avoid pitfalls, as we simplify the process of optimizing your return on investment through our expert guidance.
Involve us to help you collect insights on which asset could hold the most potential in the future.
Our 10-year forecast provides foresight for effective strategy-building for successful market entry
Our research expertise delivers real-time information that elevates your business decisions
We assist in navigating the tricky drug development terrain by providing intelligence assessments